{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:04:25Z","timestamp":1792803865821,"version":"4.5.0"},"reference-count":41,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T00:00:00Z","timestamp":1676937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Instituto de Salud Carlos III","award":["ISCIII"],"award-info":[{"award-number":["ISCIII"]}],"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Instituto de Salud Carlos III","award":["PI19\/00808"],"award-info":[{"award-number":["PI19\/00808"]}],"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Instituto de Salud Carlos III","award":["2020-1.1.6-J\u00d6V\u0150-2021-00013"],"award-info":[{"award-number":["2020-1.1.6-J\u00d6V\u0150-2021-00013"]}],"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Instituto de Salud Carlos III","award":["2020-4.1.1.-TKP2020"],"award-info":[{"award-number":["2020-4.1.1.-TKP2020"]}],"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Instituto de Salud Carlos III","award":["PI21\/00343"],"award-info":[{"award-number":["PI21\/00343"]}],"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Instituto de Salud Carlos III","award":["BFU2015-71371-R"],"award-info":[{"award-number":["BFU2015-71371-R"]}],"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Instituto de Salud Carlos III","award":["FEDER"],"award-info":[{"award-number":["FEDER"]}],"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Instituto de Salud Carlos III","award":["IJC2019-041728-I"],"award-info":[{"award-number":["IJC2019-041728-I"]}],"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"crossref"}]},{"name":"NKFIH","award":["ISCIII"],"award-info":[{"award-number":["ISCIII"]}],"id":[{"id":"https:\/\/ror.org\/03g2am276","id-type":"ROR","asserted-by":"crossref"}]},{"name":"NKFIH","award":["PI19\/00808"],"award-info":[{"award-number":["PI19\/00808"]}],"id":[{"id":"https:\/\/ror.org\/03g2am276","id-type":"ROR","asserted-by":"crossref"}]},{"name":"NKFIH","award":["2020-1.1.6-J\u00d6V\u0150-2021-00013"],"award-info":[{"award-number":["2020-1.1.6-J\u00d6V\u0150-2021-00013"]}],"id":[{"id":"https:\/\/ror.org\/03g2am276","id-type":"ROR","asserted-by":"crossref"}]},{"name":"NKFIH","award":["2020-4.1.1.-TKP2020"],"award-info":[{"award-number":["2020-4.1.1.-TKP2020"]}],"id":[{"id":"https:\/\/ror.org\/03g2am276","id-type":"ROR","asserted-by":"crossref"}]},{"name":"NKFIH","award":["PI21\/00343"],"award-info":[{"award-number":["PI21\/00343"]}],"id":[{"id":"https:\/\/ror.org\/03g2am276","id-type":"ROR","asserted-by":"crossref"}]},{"name":"NKFIH","award":["BFU2015-71371-R"],"award-info":[{"award-number":["BFU2015-71371-R"]}],"id":[{"id":"https:\/\/ror.org\/03g2am276","id-type":"ROR","asserted-by":"crossref"}]},{"name":"NKFIH","award":["FEDER"],"award-info":[{"award-number":["FEDER"]}],"id":[{"id":"https:\/\/ror.org\/03g2am276","id-type":"ROR","asserted-by":"crossref"}]},{"name":"NKFIH","award":["IJC2019-041728-I"],"award-info":[{"award-number":["IJC2019-041728-I"]}],"id":[{"id":"https:\/\/ror.org\/03g2am276","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Instituto de Salud Carlos III (ISCIII)","award":["ISCIII"],"award-info":[{"award-number":["ISCIII"]}],"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Instituto de Salud Carlos III (ISCIII)","award":["PI19\/00808"],"award-info":[{"award-number":["PI19\/00808"]}],"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Instituto de Salud Carlos III (ISCIII)","award":["2020-1.1.6-J\u00d6V\u0150-2021-00013"],"award-info":[{"award-number":["2020-1.1.6-J\u00d6V\u0150-2021-00013"]}],"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Instituto de Salud Carlos III (ISCIII)","award":["2020-4.1.1.-TKP2020"],"award-info":[{"award-number":["2020-4.1.1.-TKP2020"]}],"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Instituto de Salud Carlos III (ISCIII)","award":["PI21\/00343"],"award-info":[{"award-number":["PI21\/00343"]}],"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Instituto de Salud Carlos III (ISCIII)","award":["BFU2015-71371-R"],"award-info":[{"award-number":["BFU2015-71371-R"]}],"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Instituto de Salud Carlos III (ISCIII)","award":["FEDER"],"award-info":[{"award-number":["FEDER"]}],"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Instituto de Salud Carlos III (ISCIII)","award":["IJC2019-041728-I"],"award-info":[{"award-number":["IJC2019-041728-I"]}],"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Ministry of Economy and Competitiveness of Spain","award":["ISCIII"],"award-info":[{"award-number":["ISCIII"]}],"id":[{"id":"https:\/\/ror.org\/01txxn211","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Ministry of Economy and Competitiveness of Spain","award":["PI19\/00808"],"award-info":[{"award-number":["PI19\/00808"]}],"id":[{"id":"https:\/\/ror.org\/01txxn211","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Ministry of Economy and Competitiveness of Spain","award":["2020-1.1.6-J\u00d6V\u0150-2021-00013"],"award-info":[{"award-number":["2020-1.1.6-J\u00d6V\u0150-2021-00013"]}],"id":[{"id":"https:\/\/ror.org\/01txxn211","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Ministry of Economy and Competitiveness of Spain","award":["2020-4.1.1.-TKP2020"],"award-info":[{"award-number":["2020-4.1.1.-TKP2020"]}],"id":[{"id":"https:\/\/ror.org\/01txxn211","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Ministry of Economy and Competitiveness of Spain","award":["PI21\/00343"],"award-info":[{"award-number":["PI21\/00343"]}],"id":[{"id":"https:\/\/ror.org\/01txxn211","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Ministry of Economy and Competitiveness of Spain","award":["BFU2015-71371-R"],"award-info":[{"award-number":["BFU2015-71371-R"]}],"id":[{"id":"https:\/\/ror.org\/01txxn211","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Ministry of Economy and Competitiveness of Spain","award":["FEDER"],"award-info":[{"award-number":["FEDER"]}],"id":[{"id":"https:\/\/ror.org\/01txxn211","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Ministry of Economy and Competitiveness of Spain","award":["IJC2019-041728-I"],"award-info":[{"award-number":["IJC2019-041728-I"]}],"id":[{"id":"https:\/\/ror.org\/01txxn211","id-type":"ROR","asserted-by":"crossref"}]},{"name":"CRIS Cancer Foundation","award":["ISCIII"],"award-info":[{"award-number":["ISCIII"]}],"id":[{"id":"https:\/\/ror.org\/009yhf078","id-type":"ROR","asserted-by":"crossref"}]},{"name":"CRIS Cancer Foundation","award":["PI19\/00808"],"award-info":[{"award-number":["PI19\/00808"]}],"id":[{"id":"https:\/\/ror.org\/009yhf078","id-type":"ROR","asserted-by":"crossref"}]},{"name":"CRIS Cancer Foundation","award":["2020-1.1.6-J\u00d6V\u0150-2021-00013"],"award-info":[{"award-number":["2020-1.1.6-J\u00d6V\u0150-2021-00013"]}],"id":[{"id":"https:\/\/ror.org\/009yhf078","id-type":"ROR","asserted-by":"crossref"}]},{"name":"CRIS Cancer Foundation","award":["2020-4.1.1.-TKP2020"],"award-info":[{"award-number":["2020-4.1.1.-TKP2020"]}],"id":[{"id":"https:\/\/ror.org\/009yhf078","id-type":"ROR","asserted-by":"crossref"}]},{"name":"CRIS Cancer Foundation","award":["PI21\/00343"],"award-info":[{"award-number":["PI21\/00343"]}],"id":[{"id":"https:\/\/ror.org\/009yhf078","id-type":"ROR","asserted-by":"crossref"}]},{"name":"CRIS Cancer Foundation","award":["BFU2015-71371-R"],"award-info":[{"award-number":["BFU2015-71371-R"]}],"id":[{"id":"https:\/\/ror.org\/009yhf078","id-type":"ROR","asserted-by":"crossref"}]},{"name":"CRIS Cancer Foundation","award":["FEDER"],"award-info":[{"award-number":["FEDER"]}],"id":[{"id":"https:\/\/ror.org\/009yhf078","id-type":"ROR","asserted-by":"crossref"}]},{"name":"CRIS Cancer Foundation","award":["IJC2019-041728-I"],"award-info":[{"award-number":["IJC2019-041728-I"]}],"id":[{"id":"https:\/\/ror.org\/009yhf078","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Spanish Ministry of Science and Innovation","award":["ISCIII"],"award-info":[{"award-number":["ISCIII"]}]},{"name":"Spanish Ministry of Science and Innovation","award":["PI19\/00808"],"award-info":[{"award-number":["PI19\/00808"]}]},{"name":"Spanish Ministry of Science and Innovation","award":["2020-1.1.6-J\u00d6V\u0150-2021-00013"],"award-info":[{"award-number":["2020-1.1.6-J\u00d6V\u0150-2021-00013"]}]},{"name":"Spanish Ministry of Science and Innovation","award":["2020-4.1.1.-TKP2020"],"award-info":[{"award-number":["2020-4.1.1.-TKP2020"]}]},{"name":"Spanish Ministry of Science and Innovation","award":["PI21\/00343"],"award-info":[{"award-number":["PI21\/00343"]}]},{"name":"Spanish Ministry of Science and Innovation","award":["BFU2015-71371-R"],"award-info":[{"award-number":["BFU2015-71371-R"]}]},{"name":"Spanish Ministry of Science and Innovation","award":["FEDER"],"award-info":[{"award-number":["FEDER"]}]},{"name":"Spanish Ministry of Science and Innovation","award":["IJC2019-041728-I"],"award-info":[{"award-number":["IJC2019-041728-I"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Despite the impressive results obtained with immunotherapy in several cancer types, a significant fraction of patients remains unresponsive to these treatments. In colorectal cancer (CRC), B-RafV600 mutations have been identified in 8\u201315% of the patients. In this work we interrogated a public dataset to explore the surfaceome of these tumors and found that several genes, such as GP2, CLDN18, AQP5, TM4SF4, NTSR1, VNN1, and CD109, were upregulated. By performing gene set enrichment analysis, we also identified a striking upregulation of genes (CD74, LAG3, HLA-DQB1, HLA-DRB5, HLA-DMA, HLA-DMB, HLA-DPB1, HLA-DRA, HLA-DOA, FCGR2B, HLA-DQA1, HLA-DRB1, and HLA-DPA1) associated with antigen processing and presentation via MHC class II. Likewise, we found a strong correlation between PD1 and PD(L)1 expression and the presence of genes encoding for proteins involved in antigen presentation such as CD74, HLA-DPA1, and LAG3. Furthermore, a similar association was observed for the presence of dendritic cells and macrophages. Finally, a low but positive relationship was observed between tumor mutational burden and neoantigen load. Our findings support the idea that a therapeutic strategy based on the targeting of PD(L)1 together with other receptors also involved in immuno-modulation, such as LAG3, could help to improve current treatments against BRAF-mutated CRC tumors.<\/jats:p>","DOI":"10.3390\/curroncol30030196","type":"journal-article","created":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T05:01:32Z","timestamp":1677042092000},"page":"2569-2581","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Mapping Immune Correlates and Surfaceome Genes in BRAF Mutated Colorectal Cancers"],"prefix":"10.3390","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0929-6058","authenticated-orcid":false,"given":"Esther Caba\u00f1as","family":"Morafraile","sequence":"first","affiliation":[{"name":"Center for Biological Research Margarita Salas (CIB-CSIC), Spanish National Research Council, 28040 Madrid, Spain"},{"name":"Experimental Therapeutics Unit, Medical Oncology Department, Hospital Cl\u00ednico Universitario San Carlos (HCSC), Instituto de Investigaci\u00f3n Sanitaria San Carlos (IdISSC), 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Saiz-Ladera","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics Unit, Medical Oncology Department, Hospital Cl\u00ednico Universitario San Carlos (HCSC), Instituto de Investigaci\u00f3n Sanitaria San Carlos (IdISSC), 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Nieto-Jim\u00e9nez","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics Unit, Medical Oncology Department, Hospital Cl\u00ednico Universitario San Carlos (HCSC), Instituto de Investigaci\u00f3n Sanitaria San Carlos (IdISSC), 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5772-3766","authenticated-orcid":false,"given":"Bal\u00e1zs","family":"Gy\u0151rffy","sequence":"additional","affiliation":[{"name":"Department of Bioinformatics, Semmelweis University, 1094 Budapest, Hungary"},{"name":"2nd Department of Pediatrics, Semmelweis University, 1094 Budapest, Hungary"},{"name":"TTK Lend\u00fclet Cancer Biomarker Research Group, Institute of Enzymology, 1117 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Nagy","sequence":"additional","affiliation":[{"name":"Department of Bioinformatics, Semmelweis University, 1094 Budapest, Hungary"},{"name":"2nd Department of Pediatrics, Semmelweis University, 1094 Budapest, Hungary"},{"name":"TTK Lend\u00fclet Cancer Biomarker Research Group, Institute of Enzymology, 1117 Budapest, Hungary"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1994-2386","authenticated-orcid":false,"given":"Guillermo","family":"Velasco","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics Unit, Medical Oncology Department, Hospital Cl\u00ednico Universitario San Carlos (HCSC), Instituto de Investigaci\u00f3n Sanitaria San Carlos (IdISSC), 28040 Madrid, Spain"},{"name":"Department of Biochemistry and Molecular Biology, Complutense University, 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"P\u00e9rez-Segura","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics Unit, Medical Oncology Department, Hospital Cl\u00ednico Universitario San Carlos (HCSC), Instituto de Investigaci\u00f3n Sanitaria San Carlos (IdISSC), 28040 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1067-9630","authenticated-orcid":false,"given":"Alberto","family":"Oca\u00f1a","sequence":"additional","affiliation":[{"name":"Experimental Therapeutics Unit, Medical Oncology Department, Hospital Cl\u00ednico Universitario San Carlos (HCSC), Instituto de Investigaci\u00f3n Sanitaria San Carlos (IdISSC), 28040 Madrid, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red en Oncolog\u00eda (CIBERONC), 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.tips.2018.09.003","article-title":"Refining Early Antitumoral Drug Development","volume":"39","author":"Amir","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/nrclinonc.2010.194","article-title":"Preclinical development of molecular-targeted agents for cancer","volume":"8","author":"Ocana","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1158\/2159-8290.CD-21-0260","article-title":"Emerging Trends in Cancer Drug Discovery\u2014From Drugging the \u201cUndruggable\u201d to Overcoming Resistance","volume":"11","author":"Rudolph","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ccell.2020.12.008","article-title":"Targeting pan-essential genes in cancer: Challenges and opportunities","volume":"39","author":"Chang","year":"2021","journal-title":"Cancer Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","article-title":"Sotorasib for Lung Cancers with KRAS p.G12C Mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"786069","DOI":"10.3389\/fimmu.2021.786069","article-title":"Transcriptomic Mapping of Non-Small Cell Lung Cancer K-RAS p.G12C Mutated Tumors: Identification of Surfaceome Targets and Immunologic Correlates","volume":"12","author":"Morafraile","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"359","DOI":"10.6004\/jnccn.2018.0021","article-title":"NCCN Guidelines Insights: Colon Cancer, Version 2.2018","volume":"16","author":"Benson","year":"2018","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1093\/annonc\/mdx401","article-title":"BRAF mutant colorectal cancer: Prognosis, treatment, and new perspectives","volume":"28","author":"Argiles","year":"2017","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","article-title":"Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients with Metastatic Colorectal Cancer","volume":"26","author":"Amado","year":"2008","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"601722","DOI":"10.3389\/fonc.2021.601722","article-title":"Current Therapeutic Strategies in BRAF-Mutant Metastatic Colorectal Cancer","volume":"11","author":"Grassi","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.20.02088","article-title":"Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E\u2013Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study","volume":"39","author":"Tabernero","year":"2021","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"100328","DOI":"10.1016\/j.esmoop.2021.100328","article-title":"Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: Insights from the BEACON CRC study","volume":"6","author":"Tabernero","year":"2021","journal-title":"ESMO Open"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1158\/2159-8290.CD-20-1638","article-title":"Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies","volume":"11","author":"Aldea","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e003171","DOI":"10.1136\/jitc-2021-003171","article-title":"Role of Fc\u03b3 receptors in HER2-targeted breast cancer therapy","volume":"10","author":"Musolino","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"D\u00edaz-Rodr\u00edguez, E., Gandullo-S\u00e1nchez, L., Oca\u00f1a, A., and Pandiella, A. (2021). Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs. Cancers, 14.","DOI":"10.3390\/cancers14010154"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Juan, A., Cimas, F.J., Bravo, I., Pandiella, A., Oca\u00f1a, A., and Alonso-Moreno, C. (2020). An Overview of Antibody Conjugated Polymeric Nanoparticles for Breast Cancer Therapy. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12090802"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1158\/2159-8290.CD-20-1187","article-title":"Thinking Differently about Cancer Treatment Regimens","volume":"11","author":"Settleman","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/s43018-021-00282-w","article-title":"The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets","volume":"2","author":"Hu","year":"2021","journal-title":"Nat. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: An open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","article-title":"Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal","volume":"6","author":"Gao","year":"2013","journal-title":"Sci. Signal."},{"key":"ref_21","first-page":"E10988","article-title":"The in silico human surfaceome","volume":"115","author":"Goldmann","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Chen, E.Y., Tan, C.M., Kou, Y., Duan, Q., Wang, Z., Meirelles, G.V., Clark, N.R., and Ma\u2019Ayan, A. (2013). Enrichr: Interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinform., 14.","DOI":"10.1186\/1471-2105-14-128"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1016\/j.csbj.2021.07.014","article-title":"Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer","volume":"19","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/s41587-020-0546-8","article-title":"Visualizing and interpreting cancer genomics data via the Xena platform","volume":"38","author":"Goldman","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","article-title":"TIMER2.0 for analysis of tumor-infiltrating immune cells","volume":"48","author":"Li","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"The Cancer Genome Atlas (TCGA) Research Network (2012). Comprehensive molecular characterization of human colon and rectal cancer. Nature, 487, 330\u2013337.","DOI":"10.1038\/nature11252"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13073-016-0288-x","article-title":"NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets","volume":"8","author":"Nielsen","year":"2016","journal-title":"Genome Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.immuni.2019.08.004","article-title":"The Immune Landscape of Cancer","volume":"51","author":"Thorsson","year":"2019","journal-title":"Immunity"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1001\/jamaoncol.2016.4227","article-title":"Prognostic Survival Associated with Left-Sided vs. Right-Sided Colon Cancer: A Systematic Review and Meta-analysis","volume":"3","author":"Petrelli","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41416-019-0526-2","article-title":"Exploring the best treatment options for BRAF-mutant metastatic colon cancer","volume":"121","author":"Taieb","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"867189","DOI":"10.3389\/fimmu.2022.867189","article-title":"The Era of Cytotoxic CD4 T Cells","volume":"13","author":"Cenerenti","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"836821","DOI":"10.3389\/fonc.2022.836821","article-title":"Cancer Neoantigens: Challenges and Future Directions for Prediction, Prioritization, and Validation","volume":"12","author":"Borden","year":"2022","journal-title":"Front. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/s41571-021-00552-7","article-title":"Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways","volume":"19","author":"Kraehenbuehl","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.3389\/fonc.2019.01040","article-title":"Prognostic Value of Lymphocyte-Activation Gene 3 (LAG3) in Cancer: A Meta-Analysis","volume":"9","author":"Saleh","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Cimas, F.J., Manzano, A., Baliu-Piqu\u00e9, M., Garc\u00eda-Gil, E., P\u00e9rez-Segura, P., Nagy, A., Pandiella, A., Gy\u0151rffy, B., and Ocana, A. (2020). Genomic Mapping Identifies Mutations in RYR2 and AHNAK as Associated with Favorable Outcome in Basal-Like Breast Tumors Expressing PD1\/PD-L1. Cancers, 12.","DOI":"10.3390\/cancers12082243"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.annonc.2021.02.005","article-title":"FAST: A randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma","volume":"32","author":"Sahin","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_41","first-page":"4455","article-title":"VNN1 overexpression is associated with poor response to preoperative chemoradiotherapy and adverse prognosis in patients with rectal cancers","volume":"8","author":"Chai","year":"2016","journal-title":"Am. J. Transl. Res."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/3\/196\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:38:20Z","timestamp":1760121500000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/3\/196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,21]]},"references-count":41,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["curroncol30030196"],"URL":"https:\/\/doi.org\/10.3390\/curroncol30030196","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,21]]}}}